Results: In the LEF group, the medication was markedly effective in eight cases and effective in nine cases; the total efficacy rate was 65.30%. Blood pressure was unchanged. Une forme particulière de lupus induit par les médicaments est le lupus cutané subaigu qui est identique sur le plan clinique, immunologique et histologique à sa forme primitive. There were two cases of reversible agranulocytosis in the sulphasalazine group. Modulation of B cell expression of LRs and F-actin by LEF could be a potential therapeutic target for SLE.Over the past 60 years, overall mortality in systemic lupus erythematosus patients has dramatically decreased, but late mortality, which relates to the damage caused by the disease, its treatments and/or evolving comorbidities, is still high. Herpes zoster was the most often type among infectious events, and one case of severe lung infection was reported. After 2 yr, disease progression was significantly less with methotrexate. Furthermore, DHODH is a synthetic lethal susceptibility in several oncogenic backgrounds. To evaluate the clinical efficacy and safety of leflunomide as a new immunosuppressive medicine in lupus nephritis (LN) through a meta-analysis. Leflunomide was more effective than placebo in treatment of rheumatoid arthritis and showed similar efficacy to sulphasalazine. The antinuclear antibodies were negative. Patients who stopped leflunomide use within 30 days of neuropathy symptom onset were more likely to have improvement or recovery than those who continued taking leflunomide for a longer period (P <.001). Physicians should be vigilant in monitoring routine blood work when © 2008-2020 ResearchGate GmbH. Retrospective medical record review from Jan 1995 to Dec 2014. Plusieurs médicaments, particulièrement les diurétiques thiazidiques, peuvent être responsables d’un lupus cutané subaigu et leur arrêt permet généralement la résolution complète de l’éruption. Leflunomide also inhibited TNF-induced activation of AP-1 and the c-Jun N-terminal protein kinase activation. Interestingly, HWA 486, which did not display any immunosuppressive activity, restored the suppressed T-cell response to the same level as found in healthy mice. Nonetheless, the COMPONENT study yielded important safety and pharmacokinetic data that could provide important information regarding the use of vidofludimus in other clinical trials, not only for RA but also for other autoimmune diseases. Methods: A total of 52 patients with RNS were treated for 24 weeks between 2010 and 2014 in our hospital. Subsequently, dehydration reactions of isoxazolinols 4, employing thionyl chloride and pyridine, enabled the isolation of another series of five novel spiro-isoxazoles 5 (76–95% yield). To investigate the possible changes in B cell subsets and in B cell expression patterns of lipid rafts (LRs) and F-actin in patients with SLE and whether leflunomide treatment may have effect on these changes. Renal parameters (proteinuria, serum albumin and serum creatinine) and systemic lupus erythematosus disease activity index (SLEDAI) improved similarly in both groups. Although a treatment to target based on defined molecular pathways for specific disease subsets is appealing, this is not yet a reality. Daily administration of leflunomide (15 mg/kg/d) from 2 weeks after cGVHD induction can dramatically reduce the production of autoantibodies and immune complex deposition in the kidney, leading to relieved kidney damage and reduced mortality. This is one of the few cases of severe drug reaction after intake of leflunomide. The expression level of LRs was significantly higher in CD38(+) B cells than CD38(-) B cells and negatively correlated with C3 levels.